Balance sheet as of December 31, 2006

Profit and loss account – Year ended December 31, 2006

Declaration of interests

Platinum donors and sponsors (Donations and sponsorship from €50,000)

Alzheimer Europe is grateful to Association Luxembourg Alzheimer and the Luxembourg Ministry for Family for the secondment of the Executive Director of Alzheimer Europe and the office space they make available to the organisation free of charge.

Gold donors and sponsors (Donations and sponsorship between €20,000 and €49,999)

Alzheimer Europe is grateful to GlaxoSmithKline, Janssen-Cilag, Lundbeck and Pfizer which generously agreed to support the activities Alzheimer Europe carried out in the framework of its business plan in 2006.

Furthermore, Alzheimer gratefully acknowledges the support it has received from Lundbeck for the organisation of a carers’ survey in France, Germany, Poland, Scotland and Spain and from GlaxoSmithKline for the support of delegates to the AE conference in Paris and a workshop on the company’s research activities in the Alzheimer’s field.

Silver donors and sponsors (Donations and sponsorship between €5,000 and €19,999)

Alzheimer Europe gratefully acknowledges the support of Numico for its contribution to the European Parliament event of Alzheimer Europe and for the organisation of a workshop on the company’s research activities in the Alzheimer’s field.

Alzheimer Europe is grateful for the generous contribution of Fondation Médéric Alzheimer to the Eurocode project of Alzheimer Europe.

Alzheimer Europe is grateful to Novartis and Merck Sharp & Dohme for their support to the activities of Alzheimer Europe.

Bronze donors and sponsors (Donations and sponsorship between €1,000 and €4,999)

Alzheimer Europe is grateful to Mazars for having carried out the audit of the 2005 financial accounts of the organisation free of charge.

Support from corporate sponsors

In 2006, Alzheimer Europe had an audited income of 763,798€. Sponsorship by the pharmaceutical industry and other corporate sponsors amounted to 183,176€ or 23.98%. The following table lists sponsorship and donations received by individual companies, as well as other payments, such as speakers’ fees, honoraria and support for travel or subsistence costs. The global support received from individual companies is also presented in terms of percentages of the overall income of the organisation in line with the policy of the European Medicines Agency with regard to the transparency requirements for patients’ organisations.